Filing Flows

Filing Flows › Companies › Spero Therapeutics › Cash flow

Spero Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.4M in Q2 2026 · $19.6M over twelve months

Operating cash flow−$5.4M
Free cash flow−$5.4M

Analysis

In Q2 2026, Spero Therapeutics generated −$5.4M of operating cash flow. That is $12.3M more than in Q2 2025 (−$17.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was $19.6M; the cash balance rose by $19.6M.

Operating cash flow was −$5.4M against net income of −$9.6M. The largest differences: accrued liabilities +$3.0M, stock-based pay +$822K, prepaid and other assets +$654K.

Free cash flow

Spero Therapeutics: free cash flow by quarterSpero Therapeutics: free cash flow by quarter$12.8MQ3 2024−$23.4MQ4 2024−$4.0MQ1 2025−$17.7MQ2 2025$17.4MQ3 2025−$8.4MQ4 2025$15.9MQ1 2026−$5.4MQ2 2026
Operating cash flow less capital spending.
Spero Therapeutics: operating cash flow against capital spendingSpero Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending$12.8M$0Q3 2024−$23.4M$0Q4 2024−$4.0M$0Q1 2025−$17.7M$0Q2 2025$17.4M$0Q3 2025−$8.4M$0Q4 2025$15.9M$0Q1 2026−$5.4M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$5.4M, Capital spending $0.

Capital allocation, year by year

Spero Therapeutics: where the cash came from (up) and went (down), by fiscal yearSpero Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedFY2021: Operating cash flow −$64.3MFY2021: Shares issued $9.3M$9.3MFY2021FY2022: Operating cash flow −$7.7MFY2022: Shares issued $420K$420KFY2022FY2023: Operating cash flow −$33.0MFY2023: Shares issued $221K$221KFY2023FY2024: Operating cash flow −$23.4MFY2024FY2025: Operating cash flow −$12.6MFY2025
Over these 5 years operating cash flow totalled −$141M; the largest uses were operating cash flow ($141M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$50.8M
Debtnone
Net cash$50.8M
Cash runway2.4 years

Spero Therapeutics is burning cash: its operations consume cash, a free cash flow of −$21.4M a year at the current rate against $50.8M of cash and investments: a runway of about 2.4 years before any new financing.

Where the cash came from and went

Spero Therapeutics: sources (+) and uses (−) of cash, Q2 2026Spero Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$5.4MCash drawn (+) / kept (−)$5.4M
Spero Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Spero Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow$19.6MCash drawn (+) / kept (−)−$19.6M

From profit to cash

Spero Therapeutics: net income to operating cash flow, Q2 2026Spero Therapeutics: net income to operating cash flow, Q2 2026Net income−$9.6MStock-based pay$822KPayables−$62KAccrued liabilities$3.0MPrepaid and other assets$654KOperating cash flow−$5.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q2 2026−$5.4M$5.4M−$5.4M
Q1 2026$15.9M−$15.9M$15.9M
Q4 2025−$8.4M$8.4M−$8.4M
Q3 2025$17.4M−$17.4M$17.4M
Q2 2025−$17.7M$17.7M−$17.7M
Q1 2025−$4.0M$4.0M−$4.0M
Q4 2024−$23.4M$23.4M−$23.4M
Q3 2024$12.8M−$12.8M$12.8M

Spero Therapeutics: income statement and cash flow

Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year). The chart follows the revenue to costs, profit and cash.

Spero Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.